Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial

Retinal DiseasesFurther Publications

Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials

BMC Ophthalmol

Quiroz-Reyes MA, Quiroz-Gonzalez EA, Quiroz-Gonzalez MA, Lima-Gomez V

doi: 10.1186/s12886-025-04249-8

Macular Diseases

Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial

Ophthalmology

Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Sun X, Berliner AJ, Schulze A, Zhao M, Schmelter T, Schmidt-Ott U, Zhang X, Morgan-Warren P, Hasanbasic Z, Vitti R, Chu KW, Reed K, Bhore R, Cheng Y, Bai Z, Hirshberg B, Yancopoulos GD, Wong TY, PULSAR investigators

doi: 10.1016/j.ophtha.2025.08.022

Macular Diseases

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

Ophthalmology

Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD, PHOTON investigators

doi: 10.1016/j.ophtha.2025.10.028

Further Publications

Real-World Durability of Aflibercept 8 mg and Faricimab in Initiators Versus Switchers: A Multicenter Retrospective Analysis

Retina

Sather RN 3rd, Chiang T, Moon JY, Dev S, Belin PJ

doi: 10.1097/IAE.0000000000004813

Retinal Diseases

Effect of a Multifactorial Intervention on Retinopathy in People With Type 2 Diabetes: A Secondary Analysis of the J-DOIT3 Randomized Clinical Trial

JAMA Ophthalmol

Sasako T, Ueki K, Miyoshi K, Miyake K, Aoyama T, Okazaki Y, Ishizuka N, Yamauchi T, Noda M, Kadowaki T, J-DOIT3 Study Group

doi: 10.1001/jamaophthalmol.2025.3819

Macular Diseases

Visual Acuity and Quality of Life Outcomes with Pegcetacoplan Treatment: A Post Hoc Analysis from the OAKS and DERBY Trials

Am J Ophthalmol

Chiang A, Davis M, Stevens W, Garg S, Sheidow T, Jones DL, Intorcia M, McKeown A, Schmidt-Erfurth UM, Sarda SP, Baumal CR

doi: 10.1016/j.ajo.2025.05.023

Further Publications

Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries

Ophthalmol Retina

Lakhani M, Popovic MM, Al-Ani A, Kundapur D, Gholamian T, Chaudry E, Nanji K, Patil N, Feo A, Sadda S, Sarraf D, Ip MS, Kertes PJ, Muni RH, Adatia F, Damji KF, Chaudhary V, Hurley BR

doi: 10.1016/j.oret.2025.10.019

Surgery and Intervention

Chronic Hypotony After Tube Shunt Surgery: A Pooled Analysis of Data from Three Randomized Clinical Trials

Am J Ophthalmol

Gedde AY, Huertas L, O'Brien R, Christakis PG, Ahmed IIK, Vazquez LE, Han Y, Budenz DL, ABC, AVB, and TVT Study Groups

doi: 10.1016/j.ajo.2025.11.022

LensesFurther Publications

Capsular Tension Ring Implantation for Intraocular Lens Power Calculation in Highly Myopic Eyes: Secondary Analysis of a Randomized Clinical Trial

JAMA Ophthalmol

Lin H, Zhang J, Jin A, Zhang Y, Zhang Y, Jin L, Xu Y, Xie X, Qiu X, Dai B, Tan X, Luo L, Liu Y

doi: 10.1001/jamaophthalmol.2025.0110

Related content

Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials

Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

Real-World Durability of Aflibercept 8 mg and Faricimab in Initiators Versus Switchers: A Multicenter Retrospective Analysis

Effect of a Multifactorial Intervention on Retinopathy in People With Type 2 Diabetes: A Secondary Analysis of the J-DOIT3 Randomized Clinical Trial

Visual Acuity and Quality of Life Outcomes with Pegcetacoplan Treatment: A Post Hoc Analysis from the OAKS and DERBY Trials

Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries

Chronic Hypotony After Tube Shunt Surgery: A Pooled Analysis of Data from Three Randomized Clinical Trials

Capsular Tension Ring Implantation for Intraocular Lens Power Calculation in Highly Myopic Eyes: Secondary Analysis of a Randomized Clinical Trial